Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture
Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction (NMJ). Autoantibodies target key molecules at the NMJ, such as the nicotinic acetylcholine receptor (AChR), muscle-specific kinase (MuSK), and low-density lipoprotein receptor-related protein 4 (Lrp4), that lead by a range...
Main Authors: | Inga Koneczny, Ruth Herbst |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-07-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/8/7/671 |
Similar Items
-
New Approaches to Targeting B Cells for Myasthenia Gravis Therapy
by: Ruksana Huda
Published: (2020-02-01) -
Myasthenia Gravis With Antibodies Against Muscle Specific Kinase: An Update on Clinical Features, Pathophysiology and Treatment
by: Michelangelo Cao, et al.
Published: (2020-09-01) -
Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability
by: Masaharu Takamori
Published: (2020-05-01) -
MuSK Myasthenia Gravis—Potential Pathomechanisms and Treatment Directed against Specific Targets
by: Edyta Dziadkowiak, et al.
Published: (2024-03-01) -
Immunopathology of Autoimmune Myasthenia Gravis: Implications for Improved Testing Algorithms and Treatment Strategies
by: Hans Frykman, et al.
Published: (2020-12-01)